APYX - NASDAQ

Apyx Medical Corporation

APYX·NASDAQ

$3.79

-0.26%

HealthcareMedical - Devices

Apyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$158.70M

EPS-0.2700

P/E Ratio-14.04

Earnings Date08/06/2026

66.84M

Assets

3Y+29.0%

5Y-10.0%

10Y+90.0%

52.01M

Total Liabilities

3Y+272.0%

5Y+407.0%

10Y+485.0%

14.83M

Total Equity

3Y-61.0%

5Y-77.0%

10Y-43.0%

Apyx Medical Corporation Funding & Solvency Profile

APYX · NASDAQ

Current Assets

Cash & Cash Equivalents31.74M

Net Receivables16.78M

Inventory8.60M

Other Current Assets1.35M

Total Current Assets58 M

Non-Current Assets

Property, Plant & Equipment6.62M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets1.75M

Total Non-Current Assets8 M

Total Assets

66.84M

Financial Health Analysis

Current Ratio

5.00x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

3.51x

High financial leverage. Heavy reliance on debt may indicate increased financial risk and potential solvency concerns.

Working Capital

47 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

87% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Mixed signals: Strong short-term liquidity provides comfort, but high overall leverage requires careful monitoring of debt servicing capabilities and refinancing risk.

Apyx Medical Corporation Balance Sheet

APYX • NASDAQ

Apyx Medical Corporation Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	31.7M	31.7M	43.7M	10.2M	30.9M	41.9M	58.8M	16.5M	9.9M	14.5M	11.8M	5.7M	7.9M	4.2M	4.9M	3.8M	2.2M	2.6M	3.5M	3M
Short-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.7M	0.0	0.0	0.0	210K	948K	714K	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	31.7M	31.7M	43.7M	10.2M	30.9M	41.9M	58.8M	78.1M	9.9M	14.5M	11.8M	5.7M	7.9M	4.2M	4.9M	3.8M	2.2M	2.6M	3.5M	3M
Net Receivables	16.8M	15.5M	14M	18.2M	21.2M	17.3M	9.2M	5.1M	4.9M	4.7M	2.9M	2M	2M	2.9M	2.2M	2.1M	2.6M	3M	2.5M	2.8M
Accounts Receivables	16.8M	15.5M	14M	10.6M	13M	9.7M	8M	3.7M	4.9M	4.7M	2.9M	2M	2M	2.9M	2.2M	2.1M	2.6M	3M	2.5M	2.8M
Other Receivables	0.0	0.0	0.0	7.6M	8.1M	7.7M	1.2M	1.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Inventory	8.6M	7.6M	9.9M	11.8M	6.8M	4.1M	5.1M	5.2M	6.5M	6.2M	6M	5.7M	8.4M	8M	8.2M	7.6M	6.8M	5.8M	4.5M	3.6M
Prepaids	0.0	0.0	0.0	0.0	1.9M	2.8M	3.2M	3.3M	433K	413K	516K	210K	948K	714K	710K	966K	919K	1.1M	278.3K	402.4K
Other Current Assets	1.4M	1.7M	2.8M	2.7M	0.0	0.0	375K	130K	3M	779K	0.0	804K	545K	951K	500K	400K	800K	216.9K	603.2K	386.2K
Total Current Assets	58.5M	56.4M	70.4M	43M	60.7M	66.1M	76.7M	89.5M	22.5M	26.5M	22M	15.4M	19.8M	16M	16.5M	14.9M	13.2M	12.1M	11.5M	10.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	6.6M	6.7M	7.1M	7.6M	6.9M	7.2M	7.6M	5.8M	6.4M	6.4M	6.8M	6.9M	7.1M	7.2M	7.2M	7.4M	8.8M	7.1M	3.4M	3.2M
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	185K	185K	185K	185K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6K	1.7M	1.7M	1.8M	1.9M	2.1M	2.2M	2.3M	3.2M	4.9M	5.2M	3.9M	3.3M
Goodwill & Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	191K	1.9M	1.9M	2M	1.9M	2.1M	2.2M	2.3M	3.2M	4.9M	5.2M	3.9M	3.3M
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-150K	-187K	0.0	123K	-3.8M	120K	0.0	0.0	0.0	0.0	-530.9M	-8.2M	0.0
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	150K	187K	0.0	25K	4M	3.4M	1.8M	1.5M	1.5M	158.6K	530.9M	8.2M	0.0
Other Non-Current Assets	1.8M	1.7M	1.7M	1.2M	1.1M	807K	391K	114K	159K	212K	430K	415K	674K	1M	783K	711K	465.7K	1.3M	44.4K	21.2K
Total Non-Current Assets	8.4M	8.4M	8.9M	8.8M	8M	8M	8M	6.1M	8.4M	8.6M	9.4M	9.5M	13.4M	12.2M	11.8M	12.9M	14.4M	13.7M	7.4M	6.5M
Total Assets	66.8M	64.8M	79.2M	51.8M	68.7M	74.1M	84.7M	95.6M	31M	35.1M	31.4M	24.8M	33.2M	28.2M	28.2M	27.8M	27.6M	25.8M	18.8M	16.7M
LIABILITIES
CURRENT LIABILITIES
Total Payables	3.1M	2.6M	2.7M	4.7M	4.9M	3.8M	2.4M	1.4M	1.6M	1.6M	1.2M	1.6M	1.1M	803K	1.1M	951K	639K	1.4M	807.4K	916.3K
Accounts Payable	3.1M	2.6M	2.7M	2.7M	2.6M	1.5M	2.4M	1.4M	1.6M	1.6M	1.2M	1.6M	1.1M	803K	1.1M	951K	589K	1.3M	807.4K	916.3K
Other Payables	0.0	0.0	0.0	2.1M	2.3M	2.2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50K	78.2K	0.0	0.0
Accrued Expenses	0.0	7.1M	7.6M	6M	5.3M	4.2M	3.9M	2.5M	1.8M	823K	549K	197K	172K	304K	237K	270K	77.8K	721.7K	752.8K	743.8K
Short Term Debt	428K	0.0	0.0	0.0	0.0	0.0	140K	0.0	239K	239K	239K	239K	72K	138K	130K	140K	1.1M	125K	0.0	161.9K
Capital Lease Obligations (Current)	0.0	355K	367K	253K	287K	364K	337K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50K	0.0	0.0
Tax Payables	0.0	0.0	0.0	2.1M	2.3M	2.2M	1.5M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-78K	77.9M	0.0	0.0
Deferred Revenue	0.0	693K	488K	853K	533K	0.0	7.9M	0.0	0.0	0.0	0.0	0.0	1.2M	749K	0.0	714K	4K	24.5K	56.4K	174K
Other Current Liabilities	8.2M	0.0	1.5M	0.0	2.1M	811K	-2.5M	3.8M	2.4M	2.6M	2.1M	1.8M	1.6M	677K	937K	776K	621.2K	50.2K	86.1K	91.2K
Total Current Liabilities	11.7M	10.7M	12.7M	11.9M	13.2M	9.2M	12.2M	7.7M	6M	5.3M	4.1M	3.8M	2.9M	1.9M	2.4M	2.1M	2.5M	2.3M	1.7M	2.1M
NON-CURRENT LIABILITIES
Long Term Debt	34.8M	33.9M	33.2M	0.0	0.0	0.0	0.0	140K	2.6M	2.8M	3.1M	3.2M	3.2M	3.3M	3.6M	3.9M	4M	4.1M	0.0	0.0
Deferred Revenue (Non-Current)	1.1M	1.1M	1.2M	1.4M	1.3M	621K	0.0	-290K	0.0	0.0	0.0	9.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	150K	368K	564K	564K	564K	0.0	0.0	0.0	0.0	-531K	530.9K	8.2K	0.0
Other Non-Current Liabilities	347K	259K	198K	181K	166K	166K	519K	0.0	20K	217K	285K	3.2M	5.7M	85K	105K	0.0	0.0	-530.9K	-81.9K	418.2K
Total Non-Current Liabilities	40.3M	39.8M	39.6M	2.1M	1.5M	1.1M	1.2M	140K	3M	3.6M	3.9M	16.4M	8.9M	3.4M	3.7M	3.9M	4M	4.7M	326.3K	418.2K
Capital Lease Obligations	4.1M	4.9M	5.3M	796K	305K	676K	993K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	52M	50.5M	52.3M	14M	14.7M	10.3M	13.4M	7.8M	9M	8.9M	8M	20.1M	11.8M	5.3M	6.1M	6M	6.4M	7M	2M	2.5M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1K	0.0	1K	2K	3.2M	2.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	42K	38K	35K	35K	34K	34K	34K	34K	33K	31K	27K	18K	18K	18K	18K	18K	17K	16.8K	15.5K	15.2K
Additional Paid-In Capital	103.6M	92.1M	81.1M	73.3M	66.2M	61.1M	56.7M	52.9M	50.5M	49.6M	42.9M	29.3M	28.7M	25.5M	25.4M	25.1M	23.1M	22.8M	22.4M	22.1M
Retained Earnings	-89.1M	-77.9M	-54.4M	-35.7M	-12.6M	2.6M	14.5M	35.5M	-28.5M	-23.4M	-19.5M	-27.8M	-9.6M	-2.6M	-3.3M	-3.4M	-1.8M	-4M	-5.7M	-8.1M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-6.4M	-6.7M	-7.3M	-6.9M	-6.3M	-5.7M	-5.5M	-5M	0.0	-89K	-88.5K	-3M	-2.4M
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.0
Total Stockholders' Equity	14.5M	14.2M	26.7M	37.6M	53.7M	63.7M	71.3M	87.8M	22M	26.2M	23.4M	4.7M	21.3M	22.9M	22.1M	21.8M	21.2M	18.8M	16.8M	14.1M
Total Equity	14.8M	14.3M	26.9M	37.8M	54M	63.9M	71.3M	87.8M	22M	26.2M	23.4M	4.7M	21.3M	22.9M	22.1M	21.8M	21.2M	18.8M	16.8M	14.2M
Minority Interest	291K	125K	221K	211K	305K	138K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	120K
SUMMARY
Total Liabilities & Equity	66.8M	64.8M	79.2M	51.8M	68.7M	74.1M	84.7M	95.6M	31M	35.1M	31.4M	24.8M	33.2M	28.2M	28.2M	27.8M	27.6M	25.8M	18.8M	16.7M
Total Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.7M	-187K	0.0	123K	-3.8M	120K	714K	0.0	0.0	0.0	-530.9M	-8.2M	0.0
Total Debt	39.3M	38.8M	38.5M	796K	305K	676K	1.1M	140K	2.8M	3.1M	3.3M	3.4M	3.3M	3.4M	4.2M	4M	5.1M	4M	0.0	161.9K
Net Debt	7.6M	7M	-5.2M	-9.4M	-30.6M	-41.2M	-57.7M	-16.3M	-7.1M	-11.4M	-8.5M	-2.3M	-4.7M	-743K	-664K	197K	2.9M	1.4M	-3.5M	-2.8M
Shares Outstanding	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478	37,819,478

SEC Filings

APYX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 21, 2026	May 21, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 11, 2026	May 11, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 10, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 10, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2025 N/A	December 12, 2025	December 08, 2025	2025	View Filing
S-3 S-3 N/A	December 01, 2025	December 01, 2025		View Filing

Showing 1 to 10 of 329 filings

Related Guides

Blog Categories

Continue your APYX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.